Harlan Robins Sells 10,000 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Harlan Robins sold 10,000 shares of the stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $16.44, for a total transaction of $164,400.00. Following the sale, the insider owned 1,222,312 shares of the company’s stock, valued at $20,094,809.28. This trade represents a 0.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Adaptive Biotechnologies Stock Down 1.3%

Shares of ADPT stock opened at $15.76 on Friday. The stock has a market capitalization of $2.41 billion, a PE ratio of -29.18 and a beta of 2.18. Adaptive Biotechnologies Corporation has a 52-week low of $5.97 and a 52-week high of $20.76. The stock’s 50-day moving average price is $16.45 and its 200 day moving average price is $14.29.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.01. The company had revenue of $93.97 million during the quarter, compared to analysts’ expectations of $58.76 million. Adaptive Biotechnologies had a negative return on equity of 58.40% and a negative net margin of 31.50%.The firm’s revenue for the quarter was up 102.4% on a year-over-year basis. During the same period last year, the firm earned ($0.22) EPS. Analysts expect that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Adaptive Biotechnologies

Several institutional investors have recently modified their holdings of ADPT. AQR Capital Management LLC raised its holdings in Adaptive Biotechnologies by 45.8% during the first quarter. AQR Capital Management LLC now owns 310,272 shares of the company’s stock worth $2,265,000 after purchasing an additional 97,444 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Adaptive Biotechnologies by 4.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 68,830 shares of the company’s stock valued at $511,000 after purchasing an additional 2,914 shares during the last quarter. Teza Capital Management LLC purchased a new position in shares of Adaptive Biotechnologies in the first quarter valued at $118,000. Caxton Associates LLP acquired a new position in shares of Adaptive Biotechnologies during the 1st quarter worth $93,000. Finally, Acadian Asset Management LLC raised its stake in shares of Adaptive Biotechnologies by 44.1% during the 1st quarter. Acadian Asset Management LLC now owns 183,113 shares of the company’s stock worth $1,357,000 after buying an additional 56,058 shares during the last quarter. Hedge funds and other institutional investors own 99.17% of the company’s stock.

Wall Street Analyst Weigh In

ADPT has been the subject of several recent analyst reports. Cowen restated a “buy” rating on shares of Adaptive Biotechnologies in a research note on Wednesday. Wall Street Zen upgraded shares of Adaptive Biotechnologies from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Guggenheim began coverage on Adaptive Biotechnologies in a research report on Tuesday, September 30th. They set a “buy” rating and a $20.00 target price on the stock. BTIG Research raised their price target on Adaptive Biotechnologies from $19.00 to $21.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Finally, Piper Sandler lifted their price target on Adaptive Biotechnologies from $15.00 to $20.00 and gave the company an “overweight” rating in a research note on Wednesday, October 15th. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Adaptive Biotechnologies has a consensus rating of “Moderate Buy” and a consensus price target of $17.11.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.